drugset / Trial / NCT01206101
Efficacy and Safety of Liraglutide in Subjects With Type 1 Diabetes Undergoing Islet Cell Transplantation
RandomizedParallel-groupDouble-blindTreatment
Summary
This trial is conducted in Europe and North America. The aim of this trial is to investigate if liraglutide treatment can increase the proportion of insulin-independent subjects one year after islet cell transplantation who required only one (single-donor) islet cell transplant.
Timeline
- Start
- 2012-03-21
- Primary completion
- 2013-06-03
- Completion
- 2013-06-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Liraglutide | Peptide | 1.2 mg | Subcutaneous |
| Subject | Liraglutide | Peptide | 1.8 mg | Subcutaneous |